I have just read an interesting article from Datamonitor and through I would share it with you:
The article argues that the pharmaceutical industry’s evolving business model in response to growing regulatory constraints has so far helped it maintain profits and growth will face some serious challenges in the near future and these challenges may overcome whatever changes the industry can come up with and impact strongly on profits. The two larges challenges are the global economic downturn and the President Obama’s planned overhaul of the US health care system.
The pharam industry’s model of “pharm 2.0″ has helped it overcome reduced R&D efficiency, increased price competition and increased generic competition, but how will the industry fair against these even larger challenges.
In the US (the worlds largest drug market) the economic downturn means that more and more people are now being left uninsured (approximately 15% of the population) and public provision will have to grow to accommodate them, but budget constraints will lead to increased pressure to abandon expensive brands in favour of generics and biosimilars, also drug reimporting will cut into markets.
Many small companies are facing a bleak future as they are unable to raise the development capital they require. How will the industry respond to these challenges, more mega mergers, a switch away from in-licensing to internal R&D as smaller companies fail to survive long enough to delivery their technologies up stream.
Its an interesting article and worth reading in full.
If you would like more detail in this area please get in touch with Damien Bové damien.bove@idaconsultants.com
Damien Bové works as a drug development consultant (pharmaceutical or biotechnology) and regulatory consultant, we work with our clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.
For Assistance with Regulatory Planning and Exicution of Clinical Trials Click Here
Damien Bové is THE Drug Development and Regulatory Consultant (pharmaceutical or biotechnology), I work with my clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.
Avoid Expensive Mistakes, Keep On Top of New and Changing Regulations for Free!
Fill Out the Short Form Below… |
Sign up for the most value add free newsource you can get for free. We spend a huge amount of time and effort monitoring the main drug / device regulators websites for changes in the regulatory environment, and capture between 20 and 40 new regulations, rules and initiatives each month, and summaries them in a fantastic FREE monthly Regulatory and Market Round Up. You can Un-Subscribe at any time and we don not share your details with anybody. You can’t afford to miss out on this service. Just fill in the form below.
“Please note that the pages on this website are designed to provide you with general information only. We make no warranties, representations or undertakings about any of its content. This includes the completeness, accuracy and fitness for any particular purpose, or the content of any third party site referred to or accessed through it. You are personally responsible for ensuring that the information is correct and we will not be held liable or accountable for any mistakes that occur.”
Pingback: Drugmakers reach deal to reduce US Medicare Coverage Gap | Drug Development Consultant and Regulatory Consultant